Ligand Pharmaceuticals Incorporated (LGND) Stock Score, Valuation & Financial Research
Ligand Pharmaceuticals Incorporated is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 37/100.
Quick answer for LGND
Ligand Pharmaceuticals Incorporated currently has a Wall Street Score of 37/100. The stored market price is $284.47. Its financial score is 30/100. Its valuation score is 4/100. These figures are a research snapshot, not a buy or sell recommendation.
What Ligand Pharmaceuticals Incorporated does
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and
LGND financial snapshot
- Wall Street Score:
- 37/100
- Current price:
- $284.47
- Market capitalization:
- $5.70B
- Revenue:
- $274.5M
- Net income:
- $153.6M
- Free cash flow:
- $48.9M
- Cash:
- $115.1M
- Total debt:
- $452.0M
- EPS:
- 6.44
- P/E ratio:
- 44.2x
- Financial score:
- 30/100
- Valuation score:
- 4/100
- Revenue score:
- 45/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $48.9M, showing positive cash generation.
- The balance sheet shows $115.1M of cash versus $452.0M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 30/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research LGND
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.